2019 ARIA Care pathways for allergen immunotherapy

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence‐based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good‐quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow‐up of patients.

[1]  S. Durham,et al.  EAACI Allergen Immunotherapy User's Guide , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[2]  J. Bousquet,et al.  Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs , 2020, Clinical and Translational Allergy.

[3]  Ayşe Arzu Yorgancıoğlu,et al.  ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye. , 2020, Turkish thoracic journal.

[4]  L. Ardusso,et al.  A Precision Medicine Approach to Rhinitis Evaluation and Management , 2020, Current Treatment Options in Allergy.

[5]  C. Pitsios,et al.  Ways to increase adherence to allergen immunotherapy , 2019, Current medical research and opinion.

[6]  P. Gergen,et al.  Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy-An NIAID/AHRQ Workshop. , 2019, The Journal of allergy and clinical immunology.

[7]  T. Keil,et al.  Allergy and atopy from infancy to adulthood: Messages from the German birth cohort MAS. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  Todor A Popov,et al.  ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy” , 2019, Allergy.

[9]  A. Arjona,et al.  How molecular diagnosis may modify immunotherapy prescription in multi-sensitized pollen-allergic children. , 2018 .

[10]  G. Del-Río Camacho,et al.  How molecular diagnosis may modify immunotherapy prescription in multi-sensitized pollen-allergic children. , 2018, Allergologia et immunopathologia.

[11]  Rosalind W. Picard,et al.  MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence , 2018, Clinical and Translational Allergy.

[12]  Y. Okamoto,et al.  Efficacy and safety of SQ house dust mite sublingual immunotherapy‐tablet in Japanese children , 2018, Allergy.

[13]  Daniel Laune,et al.  POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project , 2018, Clinical and Translational Allergy.

[14]  J. Bousquet,et al.  Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. , 2018, The journal of allergy and clinical immunology. In practice.

[15]  A. Sheikh,et al.  Treatment of allergic rhinitis using mobile technology with real‐world data: The MASK observational pilot study , 2018, Allergy.

[16]  S. Durham,et al.  Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis , 2018, Current Treatment Options in Allergy.

[17]  Boleslaw Samolinski,et al.  Electronic Clinical Decision Support System for allergic rhinitis management: MASK e‐CDSS , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  M. V. van Zelm,et al.  Epidemic Thunderstorm Asthma Protection with Five-Grass Pollen Tablet Sublingual Immunotherapy: A Clinical Trial. , 2018, American journal of respiratory and critical care medicine.

[19]  J. Bousquet,et al.  Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management , 2018, Clinical and Translational Allergy.

[20]  D. Ryan,et al.  Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in Australia , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

[21]  A. Dubois,et al.  The feasibility of an allergy management support system (AMSS) for IgE-mediated allergy in primary care , 2018, Clinical and Translational Allergy.

[22]  C. Janson,et al.  Having concomitant asthma phenotypes is common and independently relates to poor lung function in NHANES 2007–2012 , 2018, Clinical and Translational Allergy.

[23]  A. Sheikh,et al.  EAACI guidelines on allergen immunotherapy: Executive statement , 2018, Allergy.

[24]  A. Sheikh,et al.  Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy , 2018, Allergy.

[25]  A. Sheikh,et al.  EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.

[26]  Todor A Popov,et al.  The roadmap for allergology in Europe: The subspecialty of allergology as “stop‐over” on the way to a full specialty. An EAACI position statement , 2018, Allergy.

[27]  A. Sheikh,et al.  National clinical practice guidelines for allergen immunotherapy: An international assessment applying AGREE‐II , 2018, Allergy.

[28]  T. Laatikainen,et al.  Multimorbidity care model: Recommendations from the consensus meeting of the Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS). , 2018, Health policy.

[29]  A. Sheikh,et al.  Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview , 2018, Allergy.

[30]  A. Sheikh,et al.  Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project , 2018, Allergy.

[31]  T. Reinhold,et al.  Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland , 2018, Journal of medical economics.

[32]  P. Demoly,et al.  Perspectives in allergen immunotherapy: 2017 and beyond , 2018, Allergy.

[33]  A. Sheikh,et al.  Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products , 2018, Allergy.

[34]  P. Cullinan,et al.  Impact of Rhinitis on Work Productivity: A Systematic Review. , 2017, The journal of allergy and clinical immunology. In practice.

[35]  P. Devillier,et al.  Sublingual immunotherapy provides long‐term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real‐world database analysis , 2017, Allergy.

[36]  E. Valovirta,et al.  Results from the 5‐year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy , 2017, The Journal of allergy and clinical immunology.

[37]  C. Wang,et al.  [An introduction to Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision]. , 2011, Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery.

[38]  C. Carroll,et al.  Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal , 2018, PharmacoEconomics.

[39]  E. Meltzer,et al.  Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[40]  G. Canonica,et al.  Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial , 2017, Clinical and Translational Allergy.

[41]  A. Sheikh,et al.  EAACI guidelines on allergen immunotherapy: Prevention of allergy , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[42]  H. Taskinen,et al.  How to support integration to promote care for people with multimorbidity in Europe , 2017 .

[43]  M. Hew,et al.  Who's at risk of thunderstorm asthma? The ryegrass pollen trifecta and lessons learnt from the Melbourne thunderstorm epidemic. , 2017, Respiratory medicine.

[44]  Joaquim Mullol,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision , 2017, The Journal of allergy and clinical immunology.

[45]  D. Ryan,et al.  Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement , 2017, Allergy.

[46]  K. Pickett,et al.  Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal , 2017, PharmacoEconomics.

[47]  P Demoly,et al.  Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper , 2017, Allergy.

[48]  Y. Nam,et al.  Physician’s recommendation and explanation is important in the initiation and maintenance of allergen immunotherapy , 2017, Patient preference and adherence.

[49]  A. Sheikh,et al.  Allergen immunotherapy for the prevention of allergy: A systematic review and meta‐analysis , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[50]  C. Pérez-Carral,et al.  Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain , 2017, Clinical and Molecular Allergy.

[51]  Aria,et al.  Multimorbidity care model : Recommendations from the consensus meeting of the Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle ( JA-CHRODIS ) , 2017 .

[52]  Todor A Popov,et al.  ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle , 2016, Clinical and Translational Allergy.

[53]  A. Sheikh,et al.  Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies , 2016, Clinical and Translational Allergy.

[54]  T. Zuberbier,et al.  Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement , 2016, The World Allergy Organization journal.

[55]  C. Bachert,et al.  Zur Diskussion gestellt: Der Arzt und die Spezifische Immuntherapie im Spannungsfeld von Leitlinie, Wirtschaftlichkeit und Medizinrecht , 2016 .

[56]  Todor A Popov,et al.  MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. , 2016, The Journal of allergy and clinical immunology.

[57]  J. Bousquet,et al.  AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation , 2016, European Respiratory Journal.

[58]  R. Lockey,et al.  Solving the Problem of Nonadherence to Immunotherapy. , 2016, Immunology and allergy clinics of North America.

[59]  J. Bousquet,et al.  European Symposium on Precision Medicine in Allergy and Airways Diseases: Report of the European Union Parliament Symposium (October 14, 2015) , 2016, Allergy.

[60]  J. Bousquet,et al.  European symposium on precision medicine in allergy and airways diseases: report of the European Union parliament symposium (October 14, 2015). , 2015, Rhinology.

[61]  J. Bousquet,et al.  Allergen Immunotherapy (AIT): a prototype of Precision Medicine , 2015, The World Allergy Organization journal.

[62]  F. Rodenas,et al.  MACVIA‐ARIA Sentinel NetworK for allergic rhinitis (MASK‐rhinitis): the new generation guideline implementation , 2015, Allergy.

[63]  C. Bachert,et al.  Allergen immunotherapy on the way to product-based evaluation—a WAO statement , 2015, The World Allergy Organization journal.

[64]  T. Kyle,et al.  Understanding the role of the healthcare professional in patient self-management of allergic rhinitis , 2015, SAGE open medicine.

[65]  P. Demoly,et al.  Clinical contraindications to allergen immunotherapy: an EAACI position paper , 2015, Allergy.

[66]  G. Canonica,et al.  The perception of allergen-specific immunotherapy among pediatricians in the primary care setting , 2015, Clinical and Molecular Allergy.

[67]  S. M. Simões,et al.  Pulmonary function and symptoms in asthmatics adolescents , 2015, The World Allergy Organization Journal.

[68]  G. Onder,et al.  Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS). , 2015, European journal of internal medicine.

[69]  Sonya Malekzadeh,et al.  Clinical Practice Guideline , 2015, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[70]  S. Walsh,et al.  Clinical Practice Guideline , 2015, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[71]  H. Sitter,et al.  Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases , 2014, Allergo Journal International.

[72]  R. Faria,et al.  Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[73]  S. Simoens,et al.  Economic burden of inadequate management of allergic diseases in the European Union: a GA2LEN review , 2014, Allergy.

[74]  A. Bozek,et al.  Grass Pollen Sublingual Immunotherapy: A Double-Blind, Placebo-Controlled Study in Elderly Patients with Seasonal Allergic Rhinitis , 2014, American journal of rhinology & allergy.

[75]  D. Postma,et al.  Integrated care pathways for airway diseases (AIRWAYS-ICPs) , 2014, European Respiratory Journal.

[76]  T. Zuberbier,et al.  Recommendations for the allergy management in the primary care , 2014, Allergy.

[77]  C. Robertson,et al.  Outcomes of childhood asthma to the age of 50 years. , 2014, The Journal of allergy and clinical immunology.

[78]  M. Blaiss,et al.  The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: patients' experience with allergen immunotherapy. , 2014, Allergy and asthma proceedings.

[79]  J. Bousquet,et al.  Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. , 2014, Allergy.

[80]  A. Buist,et al.  Complementing the randomized controlled trial evidence base. Evolution not revolution. , 2014, Annals of the American Thoracic Society.

[81]  J. Sastre.  Molecular diagnosis and immunotherapy. , 2013, Current opinion in allergy and clinical immunology.

[82]  A. Sheikh,et al.  Improving allergy management in the primary care network – a holistic approach , 2013, Allergy.

[83]  B. Kaambwa,et al.  A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. , 2013, Health technology assessment.

[84]  D. Ryan,et al.  Allergy management in primary care across European countries – actual status , 2013, Allergy.

[85]  E. Meltzer.  Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions. , 2013, Allergy and asthma proceedings.

[86]  James L. Netterville,et al.  Clinical Practice Guideline , 2013, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[87]  J. Bousquet,et al.  Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. , 2013, The Journal of allergy and clinical immunology.

[88]  A. Adler,et al.  NICE guidance on omalizumab for severe asthma. , 2013, The Lancet. Respiratory medicine.

[89]  G. Canonica,et al.  Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: a survey. , 2013, Respiratory medicine.

[90]  S. Durham,et al.  Efficacy and safety of the SQ‐standardized grass allergy immunotherapy tablet in mono‐ and polysensitized subjects , 2013, Allergy.

[91]  J. Bousquet,et al.  Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? , 2013, Allergy.

[92]  I. Rafi,et al.  Identifying current training provision and future training needs in allergy available for UK general practice trainees: national cross-sectional survey of General Practitioner Specialist Training programme directors. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[93]  W. Hop,et al.  Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. , 2012, The Journal of allergy and clinical immunology.

[94]  Giovanni Passalacqua,et al.  This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnostics , 2013 .

[95]  J. Bousquet,et al.  Impact of Allergic Rhinitis Symptoms on Quality of Life in Primary Care , 2012, International Archives of Allergy and Immunology.

[96]  J. Bousquet,et al.  A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. , 2012, The Journal of allergy and clinical immunology.

[97]  S. Durham,et al.  Rhinitis , sinusitis , and upper airway disease SQ-standardized sublingual grass immunotherapy : Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial , 2012 .

[98]  J. Bousquet,et al.  GA2LEN/EAACI pocket guide for allergen‐specific immunotherapy for allergic rhinitis and asthma , 2010, Allergy.

[99]  Allergy – will we ever meet the unmet need? , 2010, Journal of the Royal Society of Medicine.

[100]  Holger J Schünemann,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. , 2010, The Journal of allergy and clinical immunology.

[101]  F. Hampel,et al.  Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[102]  N. Chavannes,et al.  The International Primary Care Respiratory Group (IPCRG) Research Needs Statement 2010. , 2010, Primary care respiratory journal : journal of the General Practice Airways Group.

[103]  J. Bousquet,et al.  Risk of first‐generation H1‐antihistamines: a GA2LEN position paper , 2010, Allergy.

[104]  R. Lockey,et al.  Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. , 2010, The Journal of allergy and clinical immunology.

[105]  J. Bousquet,et al.  Unmet needs in severe chronic upper airway disease (SCUAD). , 2009, The Journal of allergy and clinical immunology.

[106]  J. Banks,et al.  Seasonal Allergic Rhinitis Is Associated With a Detrimental Effect on Examination Performance in United Kingdom Teenagers: Case-Control Study , 2008, Pediatrics.

[107]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[108]  H. Malling,et al.  Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. , 2007, The Journal of allergy and clinical immunology.

[109]  A. Sheikh,et al.  Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. , 2007, The Journal of allergy and clinical immunology.

[110]  J. Bousquet,et al.  Predicting and evaluating response to omalizumab in patients with severe allergic asthma. , 2007, Respiratory medicine.

[111]  A. Sheikh,et al.  Undergraduate allergy teaching in a UK medical school: comparison of the described and delivered curriculum. , 2007, Primary care respiratory journal : journal of the General Practice Airways Group.

[112]  T. Casale,et al.  Allergy immunotherapy for primary care physicians. , 2006, The American journal of medicine.

[113]  J. Bousquet,et al.  Standards for practical allergen‐specific immunotherapy , 2006, Allergy.

[114]  S. Durham,et al.  Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. , 2006, The Journal of allergy and clinical immunology.

[115]  D. Price,et al.  International Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in primary care. , 2006, Primary care respiratory journal : journal of the General Practice Airways Group.

[116]  A. Narkus,et al.  Efficacy and safety of preseasonal‐specific immunotherapy with an aluminium‐adsorbed six‐grass pollen allergoid , 2005, Allergy.

[117]  A. Gray,et al.  European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use , 2008 .

[118]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[119]  S. Durham,et al.  NHS allergy services in the UK: proposals to improve allergy care. , 2002, Clinical medicine.

[120]  Erkka Valovirta,et al.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.

[121]  J. Bousquet,et al.  Specific immunotherapy in rhinitis and asthma. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[122]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[123]  T. Molen,et al.  The founding of the International Primary Care Respiratory Group (IPCRG) , 2000 .

[124]  R. Aalberse.  Clinical relevance of carbohydrate allergen epitopes , 1998, Allergy.

[125]  Giorgio Walter Canonica,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .

[126]  H. Campbell,et al.  Integrated care pathways , 1998, BMJ.

[127]  J. Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[128]  [WHO position paper. "Allergen immunotherapy: therapeutic vaccines for allergic diseases"]. , 1998, Arerugi = [Allergy].

[129]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[130]  D. Ikle,et al.  Studies of allergen extract stability: the effects of dilution and mixing. , 1996, The Journal of allergy and clinical immunology.

[131]  R. Lockey,et al.  Survey of fatalities from skin testing and immunotherapy 1985-1989. , 1993, The Journal of allergy and clinical immunology.

[132]  G. Barbezat.  The Department of Medicine. , 1987, New Zealand hospital.

[133]  Robert S. Pinals,et al.  A double‐blind, placebo‐controlled trial , 1986 .

[134]  J. Pepys.  Occupational asthma: review of present clinical and immunologic status. , 1980, The Journal of allergy and clinical immunology.